• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

GLYBURIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • GLYBURIDE chembl:CHEMBL472 Approved

    Alternate Names:

    DIABETAMIDE 5
    MALIX
    GLYNASE
    CALABREN
    GLIBENCLAMIDE
    HB 419
    U-26452
    U-26,45
    GLYNASE PRESTAB
    MICRONASE
    DIABETA
    LIBANIL
    DAONIL
    DIABETAMIDE 2.5
    GLYBURIDE
    LEDERGLIB
    HB-419
    EUGLUCON
    SEMI-DAONIL
    GLYBURIDE (MICRONIZED)
    GLIKEN
    DIABETA®
    GLIBENCLAMIDUM
    1-(P-(2-(5-CHLORO-2-METHOXYBENZAMIDO)ETHYL)BENZENESULFONYL)-3-CYCLOHEXYLUREA
    5-CHLORO-N-(2-(4-((((CYCLOHEXYLAMINO)CARBONYL)AMINO)SULFONYL)PHENYL)ETHYL)-2-METHOXYBENZAMIDE
    1-((P-(2-(5-CHLORO-O-ANISAMIDO)ETHYL)PHENYL)SULFONYL)-3-CYCLOHEXYLUREA
    GLIBENCLAMIDA
    GLYNASE®
    chembl:CHEMBL472
    chemidplus:10238-21-8
    drugbank:01016
    pubchem.compound:3488
    rxcui:4815

    Drug Info:

    Drug Class hypoglycemic agents
    Year of Approval 1984
    FDA Approval 1984
    Drug Class small molecule
    Drug Indications Hypoglycemic Agents
    FDA Approval approved
    Drug Indications antidiabetic
    (6 More Sources)

    Publications:

    Li Q et al., 2014, KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients., Clin Exp Pharmacol Physiol
    Klen J et al., 2014, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients., Eur J Clin Pharmacol
    Javorsky M et al., 2012, KCNJ11 gene E23K variant and therapeutic response to sulfonylureas., Eur J Intern Med
    Sesti G et al., 2006, The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes., J Clin Endocrinol Metab
    Gloyn AL et al., 2001, Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)., Diabet Med
    Jabůrek et al., 1998, State-dependent inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate., J. Biol. Chem.
    Babenko et al., 2002, SUR-dependent modulation of KATP channels by an N-terminal KIR6.2 peptide. Defining intersubunit gating interactions., J. Biol. Chem.
    Serrano-Martín et al., 2006, Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis., Antimicrob. Agents Chemother.
    Ueda et al., 1999, Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide., Proc. Natl. Acad. Sci. U.S.A.
    Hambrock et al., 2002, Four novel splice variants of sulfonylurea receptor 1., Am. J. Physiol., Cell Physiol.
    Nielsen et al., 2002, 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells., J. Med. Chem.
    Hambrock et al., 2002, Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides., Br. J. Pharmacol.
    Dabrowski et al., 2002, The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener., Diabetes
    Zhang YF et al., 2005, [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]., Yao Xue Xue Bao
    Abu-Hamdah et al., 2004, Regulation of the water channel aquaporin-1: isolation and reconstitution of the regulatory complex., Cell Biol. Int.
    Sireci et al., 1999, Effects of glyburide-cyclosporin A interaction on interleukin-2 production in rats., Immunopharmacol Immunotoxicol
    Carette C et al., 2011, Diabetes mellitus and glucose-6-phosphate dehydrogenase deficiency: from one crisis to another., Diabetes Metab
    Vinzio S et al., 2004, Glibenclamide-induced acute haemolytic anaemia revealing a G6PD-deficiency., Diabetes Res Clin Pract
    Meloni G et al., 1996, Glyburide-induced acute haemolysis in a G6PD-deficient patient with NIDDM., Br J Haematol
    Youngster I et al., 2010, Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review., Drug Saf
    Kharbanda C et al., 2015, Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect., Bioorg Med Chem Lett
    Spraggs C et al., 2007, Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar., Pharmacogenet Genomics
    Ren Q et al., 2016, Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes., Diabetes Technol Ther
    Kern et al., 1993, Increased muscle glucose uptake in response to chronic glyburide treatment is not related to changes in glucose transporter (GLUT4) protein., Int. J. Biochem.
  • GLYBURIDE   AQP1

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14759764


    Sources:
    NCI

  • GLYBURIDE   ABCC8

    Interaction Score: 2.42

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name glyburide + metformin,Glucovance
    Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

    PMIDs:
    12213829 17015627 9990013 12107069 12213059 12145099 12031979


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • GLYBURIDE   KCNJ11

    Interaction Score: 1.47

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

    PMIDs:
    25115353 24442125 22385882 16595597 11318841 9593694


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • GLYBURIDE   SCNN1B

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18004211


    Sources:
    PharmGKB

  • GLYBURIDE   ABCC5

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27403931


    Sources:
    PharmGKB

  • GLYBURIDE   KCNJ1

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • GLYBURIDE   G6PD

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21147013 15126005 8562390 20701405


    Sources:
    PharmGKB FDA

  • GLYBURIDE   IL2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10466081


    Sources:
    NCI

  • GLYBURIDE   SLC2A4

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8224371


    Sources:
    NCI

  • GLYBURIDE   PPARG

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26384286


    Sources:
    DTC

  • GLYBURIDE   CYP2C9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24442125 16342679


    Sources:
    DTC PharmGKB

  • GLYBURIDE   NR1I2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GLYBURIDE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • GLYBURIDE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • GLYBURIDE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: GLIBENCLAMIDE

    • Version: 01-August-2011

    Alternate Names:
    GLIBENCLAMIDE Primary Drug Name

    Drug Info:
    Year of Approval 1984
    Drug Class hypoglycemic agents

    Publications:

  • TdgClinicalTrial: GLIBENCLAMIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Hypoglycemic Agents
    Drug Class small molecule
    FDA Approval 1984

    Publications:

  • TdgClinicalTrial: GLYBURIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidiabetic
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • NCI: GLYBURIDE

    • Version: 14-September-2017

    Alternate Names:
    C29076 NCI drug code

    Drug Info:

    Publications:
    Abu-Hamdah et al., 2004, Regulation of the water channel aquaporin-1: isolation and reconstitution of the regulatory complex., Cell Biol. Int.
    Sireci et al., 1999, Effects of glyburide-cyclosporin A interaction on interleukin-2 production in rats., Immunopharmacol Immunotoxicol
    Kern et al., 1993, Increased muscle glucose uptake in response to chronic glyburide treatment is not related to changes in glucose transporter (GLUT4) protein., Int. J. Biochem.

  • DTC: GLYBURIDE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL472 ChEMBL Drug ID

    Drug Info:

    Publications:
    Kharbanda C et al., 2015, Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect., Bioorg Med Chem Lett

  • PharmGKB: glibenclamide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Klen J et al., 2014, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients., Eur J Clin Pharmacol
    Sesti G et al., 2006, The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes., J Clin Endocrinol Metab
    Gloyn AL et al., 2001, Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)., Diabet Med

  • TTD: Glibenclamide

    • Version: 2020.06.01

    Alternate Names:
    D05LYX TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL472

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL472

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Glyburide

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21